Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190345 | 0.82 | — | — | |
| SCHEMBL28812505 | 0.79 | — | — | |
| Iodide SCHEMBL7099467 | 0.79 | — | — | |
| Water SCHEMBL7537804 | 0.79 | — | — | |
| SCHEMBL30661008 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL1268973 | 0.79 | — | — | |
| Oxalic Acid SCHEMBL9096754 | 0.74 | — | — | |
| Oxalic Acid SCHEMBL10435669 | 0.74 | — | — | |
| Pyrrole SCHEMBL4467302 | 0.74 | — | — | |
| SCHEMBL28458457 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124946-B1 | THE USE OF N-METHYL PYRIDINIUM DERIVATIVES FOR HEPATOPROTECTION | HEPENDO SP Z O O (PL) | 2012-05-23 | — | — | EP | disclosed |
| US-7893095-B2 | Treatment or prevention of diseases or conditions associated with vascular endothelium dysfunction or liver injury; 1,4-dimethylpyridinium Chloride; diabetes, metabolic syndrome, atherosclerosis | TRIGENDO SP. Z O.O. (PL) | 2011-02-22 | — | — | US | disclosed |
| EP-2124946-A1 | THE USE OF QUATERNARY PYRIDINIUM COMPOUNDS FOR VASOPROTECTION AND/OR HEPATOPROTECTION | Trigendo Sp. Z O.o. (PL) | 2009-12-02 | — | — | EP | disclosed |
| US-20080221172-A1 | Use of Quaternary Pyridinium Compounds for Vasoprotection and/or Hepatoprotection | TRIGENDO SP. Z O.O. | 2008-09-11 | — | — | US | disclosed |
| WO-2008104920-A1 | THE USE OF QUATERNARY PYRIDINIUM COMPOUNDS FOR VASOPROTECTION AND/OR HEPATOPROTECTION | TRIGENDO SP. Z O.O. (PL) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221172-A1 | Use of Quaternary Pyridinium Compounds for Vasoprotection and/or Hepatoprotection | PLPBP, PYGL, PRDX5 | TSHR 2774/4885NAPRT 1915/4885TDP1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.